Vertex Pharmaceuticals Foreign currency effect remained flat by 0.0% to $10.98M in Q4 2025 compared to the prior quarter.
An increase or decrease reflects external macroeconomic volatility rather than changes in the underlying tax strategy or risk profile.
This metric captures the impact of fluctuations in foreign currency exchange rates on the valuation of unrecognized tax...
Standard disclosure for multinational companies with significant cross-border tax exposures.
other_unrecognized_tax_benefits_increases_resulting_from_0e6d84| FY'23 | FY'25 | |
|---|---|---|
| Value | $300.00K | $43.90M |
| YoY Change | — | >999% |